Inovio Pharmaceuticals, Inc. INO PHARMA

Q: What is the current share price of Inovio Pharmaceuticals, Inc. (INO)?

As of 2026-09-19 21:16 PDT, Inovio Pharmaceuticals, Inc. (INO) trades at $1.42 on NasdaqCM. Its 52-week range is $0.66 to $2.87.

Q: What is the market capitalisation of INO?

Inovio Pharmaceuticals, Inc. (INO) has a market capitalisation of $146.82M on NasdaqCM.

Q: What is the P/E ratio of INO?

INO trades at a trailing price-to-earnings (P/E) ratio of -1.38. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 23.40.

Q: Is INO a good stock to buy?

This page provides a data-driven analysis of Inovio Pharmaceuticals, Inc. (INO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.inovio.com

Company Profile ↓

$1.42

-16.47% 1Y

Mkt Cap$146.82M

P/E-1.38

P/B23.40

52W High$2.87

52W Low$0.66

Book Value$0.05

EPS (TTM)$-1.03

Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 23.2% per year over the last five years.

Recent Developments

Dec 2025 Revenue of $65.34K (-70.0% YoY); net profit $-84.95M.
Trailing 12 Months Year-on-year growth — revenue -70.0%.
5-Year Trend Long-term compounding — revenue CAGR -81.5%, profit CAGR 23.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-81.47%
1 Year:	-69.99%

Compounded Profit Growth

5 Years:	23.21%
1 Year:	-

Stock Price Performance

1 Year:	-16.47%
6 Months:	-17.92%
3 Months:	+30.28%
1 Month:	+111.94%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 34% of range

$0.66 $2.87

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)70.08 · Overbought

Price Performance

1M+111.94%

3M+30.28%

6M-17.92%

1Y-16.47%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Profit CAGR of 23.2% over 5 years.

CONS

Revenue declined at -81.5% CAGR over 5 years.
Trading 50.5% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-1.38

Industry PE

24.83

Forward P/E

-3.23

PEG Ratio

Book Value

$0.05

Price to Book

23.40

P/S

inf

EV/EBITDA

-1.24

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-81.47%

Profit 5Y

23.21%

Revenue (YoY)

-69.99%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

-84.23%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.28

EPS (TTM)

$-1.03

Balance Sheet & Liquidity

Debt/Equity

1.83

Quick Ratio

0.92

Current Ratio

1.00

Debt

$8.00M

Total Assets

$49.78M

Current Assets

Working Capital

Ownership

Promoter Holding

0.33%

Chg in Prom Hold

-0.05%

FII / Inst Holding

46.01%

Chg in FII Hold

1.52%

Financial Snapshot

Enterprise Value

$146.82M

Total Revenue (TTM)

EBITDA

$-77.93M

Free Cash Flow

$-33.86M

Operating Cash Flow

$-80.58M

Shares Outstanding

103.40M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	INO Inovio Pharmaceuticals, Inc. PHARMA	1.42	-1.38	$146.82M	0.00%	-	-	-81.47%	23.21%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	10.38M	20.41M	2.64M	8.79M	1.53M	24.45M	2.00M	2.50M	2.83M	135.67K	866.86K	279.49K	1.33M	267.19K	236.18K	5.58M	371.12K	272.82K	291.70K	199.07K	784.39K	9.15M	114.94K	225.97K	388.45K	0	100.76K	0	65.34K	0	0	0
Operating Income	-8.37M	-15.12M	3.73M	-14.53M	-15.45M	-18.23M	-20.20M	-22.36M	-21.93M	-9.64M	-29.19M	-22.89M	-32.75M	-5.20M	-26.64M	-29.50M	-28.54M	-28.20M	-23.95M	-30.42M	-25.23M	-33.18M	-36.33M	-29.34M	-52.55M	-83.20M	-59.95M	-71.73M	-104.14M	-35.76M	-43.95M	-37.04M	-35.55M	-31.48M	-33.20M	-27.35M	-25.05M	-23.08M	-21.21M	-21.95M
Net Income	-10.58M	-6.25M	5.59M	-17.95M	-8.04M	-18.70M	-20.76M	-26.23M	-23.09M	-9.48M	-34.13M	-21.51M	-32.35M	-6.64M	-25.02M	-	-29.22M	-29.39M	-23.09M	-37.66M	-32.54M	-128.70M	19.17M	-24.34M	-54.40M	-82.14M	-60.17M	-79.07M	-108.50M	-37.78M	-40.65M	-35.53M	-33.93M	-30.47M	-32.24M	-25.17M	-19.69M	-23.52M	-45.50M	-19.68M
Diluted EPS	-0.18	-0.09	0.07	-0.25	-0.11	-0.26	-0.28	-0.36	-0.31	-0.13	-0.40	-0.24	-0.36	-0.08	-0.27	-0.34	-0.30	-0.30	-0.25	-0.38	-0.26	-0.83	0.11	-0.14	-0.27	-0.39	-0.29	-0.36	-0.46	-0.15	-1.89	-1.61	-1.52	-1.31	-1.19	-0.89	-0.51	-0.61	-0.87	-0.28
R&D Expense	9.43M	16.69M	16.08M	15.60M	18.19M	19.63M	26.98M	23.91M	24.54M	23.88M	25.51M	24.64M	24.58M	22.46M	21.85M	26.37M	24.39M	22.49M	19.14M	22.00M	19.11M	22.38M	26.46M	26.30M	39.04M	70.81M	47.09M	55.98M	56.46M	33.09M	30.18M	23.74M	15.50M	20.91M	23.09M	18.73M	16.09M	14.52M	13.33M	14.07M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	9.12M	6.14M	9.80M	4.12M	13.47M	10.46M	40.57M	35.37M	42.22M	30.48M	4.11M	7.41M	-	10.26M	832.01K	217.76K	65.34K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	277.84M	134.26M	112.62M	86.89M
Operating Income	-13.96M	-19.22M	-21.64M	-23.49M	-19.54M	-39.50M	-34.28M	-76.24M	-83.64M	-94.09M	-111.11M	-124.08M	-	-267.57M	-133.43M	-112.40M	-86.82M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-270.90M	-130.39M	-103.95M	-81.96M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	1.25M	1.22M	177.83K	0
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-277.65M	-135.12M	-107.25M	-84.95M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net Income	-24.41M	-17.61M	-15.25M	-19.67M	-66.03M	-36.12M	-29.19M	-73.74M	-88.21M	-96.97M	-119.36M	-166.41M	-	-279.82M	-135.12M	-107.25M	-84.95M
Diluted EPS	-	-	-	-0.58	-1.43	-0.64	-0.44	-1.01	-1.09	-1.05	-1.21	-1.07	-	-14.04	-6.09	-3.95	-1.81
R&D Expense	9.41M	13.26M	20.03M	17.98M	21.37M	34.10M	57.79M	88.71M	98.57M	95.26M	88.02M	94.25M	249.24M	187.65M	86.68M	75.62M	54.21M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	56.07M	61.11M	45.14M	88.29M	131.79M	213.84M	173.71M	187.24M	131.11M	143.95M	539.77M	495.94M	348.53M	170.95M	113.20M	74.31M
Total Equity	19.11M	61.18M	46.50M	47.31M	34.35M	52.46M	111.23M	175.69M	123.28M	142.39M	86.94M	3.44M	461.14M	399.67M	222.36M	117.35M	68.50M	24.10M
Cash & Equivalents	14.12M	30.30M	20.00M	17.35M	5.65M	33.72M	40.54M	57.63M	19.14M	23.79M	23.69M	22.20M	250.73M	71.14M	46.33M	14.31M	65.81M	44.27M
Total Liabilities	-	-	8.97M	13.24M	10.28M	35.38M	20.25M	37.91M	50.33M	44.75M	44.08M	138.55M	78.63M	96.27M	126.17M	53.60M	44.69M	50.21M
Current Liabilities	-	-	6.44M	11.04M	8.38M	28.97M	14.09M	31.47M	43.82M	35.41M	35.30M	31.99M	41.71M	65.74M	96.87M	42.57M	35.33M	43.67M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-14.08M	-11.94M	-19.76M	-22.31M	-15.38M	-29.82M	-12.44M	-62.56M	-63.21M	-73.55M	-97.85M	-177.98M	-215.71M	-216.22M	-124.37M	-104.08M	-88.63M
Investing Cash Flow	1.45M	11.44M	-10.90M	5.28M	-9.24M	-35.81M	-54.82M	16.27M	-27.83M	42.42M	-9.04M	-58.80M	-175.34M	109.59M	87.36M	104.07M	14.04M
Financing Cash Flow	28.60M	-9.69M	28.01M	5.33M	52.69M	72.46M	84.35M	7.79M	95.69M	31.04M	105.40M	465.28M	211.50M	81.84M	5.00M	51.48M	53.05M
Capital Expenditure	-48.37K	-181.65K	-161.19K	-240.99K	-176.93K	-1.38M	-2.78M	-2.74M	-10.29M	-2.09M	-987.93K	-1.52M	-1.23M	-969.15K	-320.90K	-487.83K	-285.70K
Free Cash Flow	-14.13M	-12.12M	-19.92M	-22.55M	-15.56M	-31.20M	-15.22M	-65.29M	-73.50M	-75.64M	-98.84M	-179.50M	-216.94M	-217.18M	-124.69M	-104.56M	-88.92M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-153.0%	-312.8%	-220.9%	-570.4%	-145.1%	-377.7%	-84.5%	-215.5%	-198.1%	-308.7%	-2,702.1%	-1,674.2%	-	-2,607.4%	-16,036.7%	-51,616.9%	-132,871.3%
Net Margin %	-267.7%	-286.6%	-155.7%	-477.6%	-490.3%	-345.4%	-71.9%	-208.5%	-208.9%	-318.1%	-2,902.8%	-2,245.4%	-	-2,726.7%	-16,239.9%	-49,254.3%	-130,000.0%
ROE %	-39.9%	-37.9%	-32.2%	-57.3%	-125.9%	-32.5%	-16.6%	-59.8%	-61.9%	-111.5%	-3,474.7%	-36.1%	-	-125.8%	-115.1%	-156.6%	-352.5%
ROCE %	-	-38.7%	-43.2%	-63.9%	-32.9%	-33.6%	-18.8%	-58.7%	-55.1%	-98.2%	-99.2%	-24.9%	-	-106.3%	-103.9%	-144.3%	-283.3%

Shareholding Pattern

Insiders

0.33%

Institutions

46.01%

Public Float

46.17%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	8.18%	8.45M	$10.48M
2	Jupiter Topco LLC	5.00%	5.17M	$6.41M
3	Vanguard Capital Management LLC	3.53%	3.65M	$4.53M
4	Boxer Capital Management, LLC	2.75%	2.84M	$3.53M
5	Adar1 Capital Management, LLC	2.07%	2.14M	$2.66M
6	Shaw D.E. & Co., Inc.	1.31%	1.35M	$1.68M
7	Two Sigma Investments, LP	1.20%	1.24M	$1.54M
8	Eversept Partners, LP	1.00%	1.04M	$1.28M
9	Geode Capital Management, LLC	0.78%	802.75K	$995.41K
10	Millennium Management Llc	0.77%	796.11K	$987.17K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INO

Google News Wed, 29 Jul 2026

INOVIO Announces Pricing of $20.0 Million Public Offering - PR Newswire

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNTFhzTEI5ZmNIcHNLdG9BRWZySV9qY1Vjd1Y0ek5zRWVxX3FSQ2pGYjloQTJLQ1U2QXplQ1Nodkk2UHFTWDhRdkRIQkpCY1VYZ3M4dXk3b0pFZ3Q4N3pxUTQ1bE1CVkY0RTdNejhJc0ZPSnYtcFI5Z2ZYcFhUZ2NiaDdKeERxYjczZnFncT…

Google News ue, 01 Sep 2026

Investor talks begin Sept. 9 as INOVIO joins two conferences - Stock Titan

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPUnhObHliVHU0djRqa0h6cTZFM1dHeTQwWklRaklvMnhkSUttXzJTWTRWbFRKakhScW1Ub2tIa1J2Y3BhSDNRcHBZamlfelMzb0JCZjZuSkNIczdyY3gtcDRtNUtJd0xQVmhEeVRfVTJtSy10S1VGWjV3ZmN2RllkcjJpZ0Rma1BOUjJ0RT…

Google News hu, 21 May 2026

INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNMUxCTWYyMFU2WGNrVDRIcjcyeF96dWJ0U2toR1QyM1FlUHhUTG9Makx0Z2psdVRpQUp2UjFGb2dTMlBJUlJRRHdNeVhNZEhFanhoOHVCNHVVRWg5eS01Wk1neEUzZFU2cHhDUjNpU21yRVozem43QUpMN0NiOUlpeW1TTXJOeGdJZnppNU…

Google News ue, 25 Aug 2026

Inovio: The Final Countdown To A Binary FDA Decision - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQbWZodmRkYjFkOGJQWEFRbklBSjNxaVkwU3dlYjJiM2tuVmlQME9ROGQ5VE9aTE1CVDdUVlhzNVJDc2NiUnljQXRuZ2ctSEJBdlVudUJxMjkyUWJTWUUzLXJpRGtfSm5YRG5RaHVSZVlMV3ZLc2VOY2lTX2dxOVUwRWIxYWthVGZ5V0Vzcz…

Google News hu, 25 Jun 2026

INO Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBZNWhDVXdiMDdrb0tGU2pXRndUQ1A5cDBTT0VpWFdqMUlPMVQ3bkVIVkg3anZ5RVpQZE5yVVhSWDZ4aVljRi1BZm5hblppX2E2SXp3Zkk5bm5QVE05d2FOX1FyU1pHWkJfNFNjbWlvdkJZZWc2RElDUA?oc=5" target="_blank">INO F…

Google News hu, 30 Jul 2026

Inovio raises USD 20m ahead of make-or-break FDA decision on INO-3107 - AllSci

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQQVVjNnZiOHZYMl80d2FuUWZwSUlQQmw5RjN0SnFCNkNaakdOd2hfejVyc1NJRmZ6ZERHcXoybk9LMG5qUmk1QTZPTGpzczR0NHotY1ROejRySFB6eklBaENUTGpsMWZwVVV0TWJMS2d3NUdVR0VzNEdOeW9vX1gySzkzY0FwTnZ3Wk5OZX…

INO — Frequently Asked Questions

What is the current share price of Inovio Pharmaceuticals, Inc. (INO)?

As of 2026-09-19 21:16 PDT, Inovio Pharmaceuticals, Inc. (INO) trades at $1.42 on NasdaqCM. Its 52-week range is $0.66 to $2.87.

What is the market capitalisation of INO?

Inovio Pharmaceuticals, Inc. (INO) has a market capitalisation of $146.82M on NasdaqCM.

What is the P/E ratio of INO?

INO trades at a trailing price-to-earnings (P/E) ratio of -1.38. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 23.40.

Is INO a good stock to buy?

This page provides a data-driven analysis of Inovio Pharmaceuticals, Inc. (INO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Inovio Pharmaceuticals, Inc. INO PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

INOVIO Announces Pricing of $20.0 Million Public Offering - PR Newswire

Investor talks begin Sept. 9 as INOVIO joins two conferences - Stock Titan

INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial - Stocktwits

Inovio: The Final Countdown To A Binary FDA Decision - Seeking Alpha

INO Forecast — Price Target — Prediction for 2027 - tradingview.com

Inovio raises USD 20m ahead of make-or-break FDA decision on INO-3107 - AllSci

INO — Frequently Asked Questions

What is the current share price of Inovio Pharmaceuticals, Inc. (INO)?

What is the market capitalisation of INO?

What is the P/E ratio of INO?

Is INO a good stock to buy?

Explore More